OssDsign: Promising first patient report - Redeye

Redeye is encouraged by the continuous positive news flow related to Catalyst, and we embrace the just-announced first patient report from the TOP FUSION clinical trial. We summarise some key parts of the case as we go into 2023 and reiterate our SEK9.5 base case.

Länk till analysen i sin helhet: https://www.redeye.se/research/870285/ossdsign-promising-first-patient-report?utm_source=finwire&utm_medium=RSS